MRTX849 acid is primarily utilized in the development of targeted cancer therapies. It functions as a potent and selective inhibitor of KRAS G12C, a specific mutation found in various cancers, including non-small cell lung cancer (NSCLC) and colorectal cancer. By binding to the mutated KRAS protein, it effectively blocks its activity, inhibiting tumor growth and proliferation. This makes it a promising candidate for precision medicine, particularly for patients with KRAS G12C-mutated cancers who have limited treatment options. Its application is currently being explored in clinical trials to assess its efficacy, safety, and potential as a standalone or combination therapy in oncology.